Evidence map›Paper›PMID 41167373›Full record

ArticleAmerican journal of ophthalmology2026

Glaucoma Progression Detection Time Using OCT and OCTA in African and European Descendants.

Jo-Hsuan Wu, Takashi Nishida, Sasan Moghimi, Evan Walker, Linda M Zangwill, Robert N Weinreb

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jo-Hsuan WuFrom the Edward S. Harkness Eye Institute, Department of Ophthalmology, Columbia University Irving Medical Center (J.-H.W.), New York, New York.
Takashi NishidaHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California (J.-H.W., T.N., S.M., E.W., L.M.Z., R.N.W.), San Diego, La Jolla, California, USA.
Sasan MoghimiHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California (J.-H.W., T.N., S.M., E.W., L.M.Z., R.N.W.), San Diego, La Jolla, California, USA.
Evan WalkerHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California (J.-H.W., T.N., S.M., E.W., L.M.Z., R.N.W.), San Diego, La Jolla, California, USA.
Linda M ZangwillHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California (J.-H.W., T.N., S.M., E.W., L.M.Z., R.N.W.), San Diego, La Jolla, California, USA.
Robert N WeinrebHamilton Glaucoma Center, Shiley Eye Institute, Viterbi Family Department of Ophthalmology, University of California (J.-H.W., T.N., S.M., E.W., L.M.Z., R.N.W.), San Diego, La Jolla, California, USA.. Electronic address: rweinreb@ucsd.edu.

Funding

Vision BiostatisticsP30EY022589 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Derek Stuart Welsbie · 2012 to 2026
$10.3M
Diagnostic Innovations in Glaucoma:Structural AssessmentR01EY011008 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 1995 to 2015
$8.7M
Diagnostic Innovations in Glaucoma Study (DIGS): High Myopia and Advanced DiseaseR01EY027510 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI LINDA M ZANGWILL · 2017 to 2026
$5.3M
Diagnosis and Monitoring of Glaucoma with Optical Coherence Tomography AngiographyR01EY029058 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI WEINREB, ROBERT N · 2018 to 2024
$4.2M
African Descent and Glaucoma Evaluation (ADAGES) II: Glaucoma ProgressionR01EY019869 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ZANGWILL, LINDA M · 2010 to 2014
$2.8M
Age-related changes in optic nerve head structure and biomechanicsR01EY018926 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DOWNS, J CRAWFORD, GIRKIN, CHRISTOPHER ANTHONY · 2008 to 2015
$2.6M
African Descent and Glaucoma Evaluation (ADAGES) IV: Alterations of the lamina cribrosa in progressionR01EY026574 · NEI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FAZIO, MASSIMO ANTONIO, GIRKIN, CHRISTOPHER ANTHONY · 2017 to 2020
$2.6M
Monitoring of Glaucoma Patients in Advanced DiseaseR01EY034148 · NEI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Sasan Moghimi Araghi · 2022 to 2026
$2.5M
NEI NIH HHS P30 EY022589NEI NIH HHS R01 EY011008NEI NIH HHS R01 EY018926NEI NIH HHS R01 EY019869NEI NIH HHS R01 EY026574NEI NIH HHS R01 EY027510NEI NIH HHS R01 EY029058NEI NIH HHS R01 EY034148
6 · The paper itself

Abstract

purposeTo assess time to detection of glaucoma progression using optical coherence tomography (OCT) and OCT angiography (OCTA) among individuals of African descent (AD) and European descent (ED).

designRetrospective cohort study. SUBJECTS: AD and ED glaucoma subjects from the Diagnostic Innovations in Glaucoma Study (DIGS) with ≥2-year and 4 visits of OCT and OCTA imaging.

methodsLinear mixed effects model-derived OCT and OCTA variability estimates were used to simulate longitudinal data by race. We performed 2 assessments on the time to detect trend-based glaucoma progression (ie, significantly negative OCT and OCTA slope): in assessment I (racial comparison within modality), "standardized simulation" assumed the same, standardized OCT and OCTA baseline and slopes for both races, whereas "real-world simulation" used real-world racial cohort-derived baseline and slopes. In assessment II (modality comparison within race), simulation was performed with real-world racial cohort-derived OCT and OCTA baseline and quartile (p25/p50/p75) change rates. The required time and 2- and 5-year rates of progression detection using OCT and OCTA in individual races was evaluated.

resultsWe included 48 AD eyes (31 subjects) and 120 ED eyes (77 subjects), of which baseline age and VF severity were similar. In assessment I standardized simulation, with assumed OCT and OCTA slopes of -0.5 to -2.0 units/year, the time to OCT progression detection ranged from 2.4 to 5.2 years in ED and 2.6 to 5.6 years in AD (difference: <0.4 years). For OCTA, the time to progression ranged from 2.3 to 4.9 years in ED and 2.4 to 5.0 years in AD (difference: <0.2 years). In real-world simulation, with OCT slopes of -0.38 and -0.52 µm/y, the time to OCT progression was 7.0 and 5.1 years for AD and ED, respectively. For OCTA, with slopes of -0.56%/y and -0.77%/y, the time to progression was 4.3 and 3.9 years for AD and ED, respectively. In assessment II, compared with OCT, OCTA showed shorter time to progression detection (difference: 0.4-2.6 years) and higher progression rates in both races.

conclusionsUsing computer simulation, there was no racial difference in OCT and OCTA time to progression detection between AD and ED. Moreover, OCTA showed shorter time and higher rate of progression detection than OCT in both races. Although its clinical importance remains to be confirmed, our findings suggest an ancillary role of OCTA to OCT when capturing glaucoma progression across races.

Indexed as

Black PeopleFluorescein AngiographyGlaucomaGlaucoma, Open-AngleOptic DiskTomography, Optical CoherenceWhite PeopleAgedBlack or African AmericanDisease ProgressionFemaleFollow-Up StudiesHumansIntraocular PressureMaleMiddle Aged

Identifiers

PMID41167373
PMCPMC13592674

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.